Reuters logo
BRIEF-Avenue Therapeutics doses first patient in postoperative pain trial
September 27, 2017 / 12:09 PM / 3 months ago

BRIEF-Avenue Therapeutics doses first patient in postoperative pain trial

Sept 27 (Reuters) - Avenue Therapeutics Inc

* Avenue Therapeutics announces dosing of first patient in pivotal Phase 3 clinical trial of intravenous tramadol for the management of postoperative pain

* Avenue Therapeutics Inc says ‍expect to report topline data in Q2 of 2018​

* Avenue Therapeutics Inc - about 405 patients will be enrolled to IV tramadol 50 mg, IV tramadol 25 mg or placebo in a 1:1:1 ratio​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below